



ALLENEX AB (PUBL)

YEAR-END REPORT 2012

For the fourth quarter October - December

- Net sales for the quarter amounted to SEK 27.4 million (27.5). Sales were impacted by a negative currency effect of SEK 1.2 million compared to the same period last year. Adjusted for currency effects, the growth rate was 4 percent.
- Operating income (EBIT) for the quarter was SEK 0.6 million (-76.0), with currency effects having a negative impact of SEK 1.4 million on results compared to the same period last year. (In 2011, earnings were impacted by impairment losses of SEK 74.6 million.)
- Operating margin for the quarter was 2 percent.
- Earnings after tax for the quarter was SEK 0.9 million (-71.7).
- Earnings per share for the quarter, basic and diluted, were SEK 0.03 (-0.75).

For the January - December period

- Net sales for the year amounted to SEK 112.7 million (98.7), corresponding to an increase of 14 percent compared to last year. (Olerup GmbH became a part of the group on June 1, 2011). Sales compared to 2011 were impacted by a negative currency effect of SEK 2.3 million.
- Operating income (EBIT) for the year was SEK 7.9 million (-88.1), with currency effects having a negative impact of SEK 3.7 million on results compared to last year. (2011 results were charged with impairment losses of SEK 74.6 million.)
- Operating margin for the year was 7 percent.
- Earnings after tax for the year was SEK 0.3 million (-504.7). (2011 results were charged with impairment losses of SEK 489.3 million).
- Earnings per share for the year, basic and diluted, were SEK 0.04 (-7.23).

Significant events after the year end

- The Allenex subsidiary AbSorber received an EU grant of EUR 215,000 over a three-year period
- Allenex received a breakthrough order in the U.S. for SBT Resolver™ from a leading HLA typing laboratory. The yearly sales value is estimated at more than SEK 2 million.

CEO Anders Karlsson's comments on the fourth quarter 2012:

"In 2012, Allenex reset its course to focus on transplantation diagnostics. The organization is now streamlined to underpin the company's new strategy and adapted to meet the needs of our customers. Sales increased during the year and we achieved a number of key business milestones. We see continued growth in important markets for the company's largest product Olerup SSP. The roll out of the SBT Resolver™ product line from our Australian partner Conexio Genomics has been intensive and during the year several centers have adopted the product. After the year end, we received a breakthrough order in the U.S., from a major leading transplantation center, with several other key American centers shortly expected to follow suit. We see this as a key launch milestone, with the possibility of gaining other major centers in other parts of the world as customers. Unfortunately, the strong Swedish kronor has had a negative impact on sales, primarily during the second half of 2012."

For additional information, please contact:

Anders Karlsson, CEO, tel: +46 (0)70-918 00 10 or email: anders.karlsson@allenex.se


Yvonne Axelsson, CFO, tel: +46 (8) 508 939 72 or email: yvonne.axelsson@allenex.se

Group performance

Allenex is a life science company that develops, manufactures, markets and sells products on the global market that facilitate safer transplantation of organs and blood stem cells. Allenex is listed on NASDAQ OMX Stockholm, Small Cap, (ticker: ALNX). There are 54 employees in the Allenex group.

SALES

Net sales for the year were SEK 112.7 million (98.7), an increase of 14 percent compared to the previous year. Olerup GmbH became a part of the group on June 1, 2011, which means that the figures are not entirely comparable.



Sales in the fourth quarter mainly comprised HLA typing kits based on SSP technology. Compared to the third quarter 2012, sales increased by 3 percent in SEK. Net sales was impacted negatively in the fourth quarter by the increasingly stronger Swedish kronor. In total, currency effects had a negative impact of SEK 1.2 million for the quarter and SEK 2.3 million for the year. Adjusted for currency effects, turnover was 7 percent higher during the fourth quarter compared to the third quarter.

Sales in 2012 increased through the distribution company Olerup GmbH in Vienna (Europe and the rest of the world, excluding North and South America and the Nordic Region) in EUR by 8 percent compared to last year. Italy and Germany constitute the two largest markets.

In Southern Europe, there is an increasing trend towards larger and more structured tender processes. This is the case in Italy, Spain and Portugal, with France recently showing signs towards carrying out tender offerings on a larger, national basis too. Such tender contracts usually run for two- to three-year periods. During the year, Allenex, in collaboration with a local distributor in France, won a centralized tender contract issued by EFS, the French state-run tissue typing laboratories, for the delivery of SSP products over a four-year period.

Sales of Allenex products in North America through Olerup Inc increased in local currency (USD) by 1 percent compared to 2011.

Sales outside Europe and North America comprise a very small portion of total sales to date. At the same time, extensive work to register the company's products in other countries including Brazil, Mexico, South Korea and China is ongoing.

Allenex customers largely comprise HLA laboratories. Allenex segments HLA laboratories according to level of automation. The more individuals HLA tested at the laboratory, the more probable it is that the laboratory is fully automated. SSP technology is primarily used by smaller laboratories, but it is also used as complementary technology at the largest laboratories, which today use automated solutions as their primary typing technology.

MARKET DEVELOPMENT

Since 2011, Allenex is the exclusive global distributor of the HLA typing products SBT Resolver™ and Assign-SBT™ 3.6+ from Conexio Genomics Pty. The focus since then has been on introducing the new product line to the largest and most automated HLA laboratories in the U.S. and Europe. These major laboratories conduct in particular tests for bone marrow registries (such as the Swedish Tobias registry) and testing outsourced by smaller transplantation centers. The larger registry laboratories conduct HLA typing on some 5,000 – 10,000 individuals a year and are extremely thorough when evaluating a new supplier, which makes for lengthy sales processes. Purchasing patterns are also impacted by the fact that they maintain large inventories, placing orders every three to six months.

It can therefore be concluded that the period from the first customer visit to receiving an order is, at best, between six and twelve months. The tendency is that the greater the usage, the longer the evaluation and decision making process. Before a purchasing decision is made, an evaluation comparing SBT Resolver™ to the product offered by the current supplier of SBT typing is first carried out. If the evaluation is positive, then internal validation of the product is required before a final decision is made to switch suppliers. This validation process, aimed at ensuring the safety of internal routines and processes, takes from three to six months.

A contract entered into earlier between Conexio and the American company Celera ends on December 31, 2013. This is considered likely to have a favorable effect on the potential of Allenex securing a strong position in SBT typing as well. Under the terms of this agreement Celera has had the right to license the manufacturing and distribution of SBT reagents and offer Conexio's software, Assign-SBT™, to customers that use their products for SBT typing. The distributor of Celera's products, Abbot, has built up a strong market position through these

products and supplies SBT products to the equivalent of two-thirds of the HLA typing laboratories in the U.S. that use SBT technology. In Europe, the corresponding share is one third. For Allenex, as exclusive distributor of Conexio's SBT solutions, this means the opportunity to penetrate these two core markets faster and deeper. A key reason is that Assign-SBT™, used by Allenex, is an upgraded version of the software previously used exclusively for Abbott's customers. Allenex therefore sees great opportunity in converting additional laboratories to the Allenex solution.

Clinical use of Conexio Resolver SBT Resolver™ is now ongoing, with customers purchasing the product in North America and Europe. In Europe, Allenex, via its subsidiary Olerup GmbH, converted over 11 laboratories at the end of 2012, with additional customers currently at the validation and evaluation stage.

In the U.S., where HLA laboratories generally have a higher volume than those in Europe, the Allenex SBT solution is in use at 4 laboratories. Currently, 10 laboratories are at the final validation stage, with another 10 laboratories currently at evaluation stage. Of note is that after evaluation only two laboratories in the U.S. have gone with another supplier, while 12 laboratories have chosen to validate the Allenex solution over other alternatives.

PRODUCT DEVELOPMENT

Allenex SSP products are updated on an ongoing basis and the strategy is to offer solutions that are as complete as possible. In line with this, continuous product development is carried out to enable the company to keep its market leading position. In conjunction with stem cell and organ transplantation, there are currently three different techniques available to HLA type patients and donors. SSO and SBT are automated technologies and in 2012 Allenex started work on the introduction of SSP add-ons, as a complement to the automated technologies.

Going forward Allenex will strive to remain at the forefront of SSP technology by continuously and frequently updating and adapting its product portfolio and by developing new products aimed at complementing other typing methods, primarily Conexio's SBT Resolver™.

Several national and regional clinical trials have commenced both in the U.S. and Europe for the cross-match text XM-ONE®, focused on antibody detection. The trials are aimed at further demonstrating the product's clinical value. During the year, a collaboration agreement was entered into with the Heidelberg University Hospital in Germany. The hospital's transplantation center will function as a reference laboratory in Europe, through which other laboratories can order XM-ONE®-tests.

FINANCIAL RESULTS

Consolidated operating income for the year was SEK 7.9 million (-88.1). The results include realized and unrealized currency effects corresponding to a loss of SEK 3.7 million. The 2011 results were charged with impairment losses of intangible assets totaling SEK 74.6 million.

The improvement in results for the year compared to previous years is also a consequence of positive sales development, efficiency improvements in the new organization, improved margins now that Olerup GmbH is a subsidiary, and the effects of the streamlining measures that were implemented to reduce costs. Compared to last year, the cost of employee remuneration was SEK 8.5 million lower, with other costs reduced by SEK 4.5 million. (Olerup GmbH was consolidated on June 1, 2011 and is included in the results for 2012 for 12 months compared to seven months in 2011.)

The fair value for the two remaining holdings in the companies AnaMar AB and ONCOlog Medical QA AB is deemed as nil.

SIGNIFICANT EVENTS IN THE GROUP

Significant events in the first quarter

- At the end of the acceptance period on January 11, 2012, the cash offer made by Xenella Holding AB in November 2011, co-owned by Mohammed Al Amoudi and FastPartner AB (publ) had been accepted by shareholders representing 11,174,755 shares in Allenex, corresponding to 9.3 percent of the shares and votes in the company.

Significant events in the second quarter

- In April, Allenex divested its holdings in the associated company Likvor AB for a total consideration of SEK 750 thousand. Since from an accounting perspective the company was valued at nil, the transfer entails a corresponding gain in the second quarter 2012 for Allenex.
- In April, Allenex also divested its holdings in the associated company Pharmacolog i Uppsala AB for a total consideration of SEK 300 thousand. Here too, the company was valued at nil from an accounting perspective, with the transfer entailing a corresponding gain in the second quarter for Allenex.
- From May 1, Olerup GmbH started selling directly to end customers in The Netherlands and Belgium.
- In June, Tulane University Hospital, New Orleans, USA, began a study of XM-ONE® in conjunction with kidney transplantation. The estimated inclusion period is one year, after which patients will be followed up for 6 months.
- In June, the University of Miami commenced a clinical trial of XM-ONE® in conjunction with kidney

transplantation The estimated inclusion period is two years and patients will be followed up for 6 months after the transplantation.

Significant events in the third quarter

- Allenex, in collaboration with a local distributor in France, won a centralized tender contract issued by EFS, the French state-run tissue typing laboratories. The expected value of the contract for Allenex is SEK 6 million per year for four years (total SEK 24 million). As half of the laboratories encompassed by the tender are already clients today, the contract will entail a net effect or direct sales increase of around SEK 3 million per year (a total of SEK 12 million).

Significant events in the fourth quarter

- The remaining SEK 7.7 million of the company's convertible loan (KV1) was repaid without conversion.

SIGNIFICANT EVENTS AFTER THE YEAR END

- The Allenex subsidiary AbSorber, together with EUROSTAM, a consortium of European transplantation centers, has received a grant under the EU Commissions 7th Framework Programme, FP7. The purpose is to improve the results of kidney transplants among patients with higher risks of complications due to significant genetic deviation from the donor. The Allenex cross-test XM-ONE® will be used throughout the project. Of the total EU grant of EUR 2.6 million, AbSorber will receive EUR 215,000 over a three-year period.
- A leading U.S. based HLA laboratory has chosen Allenex U.S. distribution company, Olerup Inc. as supplier of sequence-based HLA typing (SBT). The laboratory, which is one of the ten largest typing laboratories in the U.S., has been evaluating and validating SBT Resolver™ from Allenex partner Conexio Genomics for some time. The laboratory has already placed its initial order, which also includes software Assign-SBT™ 3.6+. The yearly sales value of the contract is estimated at more than SEK 2 million per year.

FINANCIAL POSITION, CASH FLOW AND FINANCING

The group's operations are financed by shareholders' equity and loans. Interest-bearing liabilities amounted to SEK 99.0 million (150.0) primarily secured to finance the acquisition of Olerup SSP and AbSorber. Allenex repaid in full the convertible loan 'KV1' at an amount of SEK 40.8 million and amortized SEK 12 million of a bank loan. A bank loan of SEK 30 million as well as the SEK 31 million convertible loan from SSP Primers due on June 30, 2013 are included in the refinancing discussions that Allenex is

holding with its main bank.

The consolidated equity/assets ratio was 63 percent (53). Consolidated equity was SEK 216.2 million (219.8) equivalent to SEK 1.80 per share (1.83). Cash and cash equivalents totaled SEK 14.3 million (80.5). Cash flow from operating activities before changes in working capital was SEK 0.6 million (-25.6). This change for the positive is primarily due to an increase in sales and reduced costs.

Convertibles issued in July 2008 pledged to SSP Primers AB.

The convertibles amount to SEK 31 million maturing on June 30, 2013, carrying an annual interest rate of 6 percent, with a conversion rate of SEK 35.72.

Risks and uncertainties

Allenex has long been a well established business with well-known products in the field of genomic HLA typing based on SSP technology, maintaining a significant market share. At the same time, the company faces market risk in the form of competition from other producers, the transition to more automated typing processes as well as new technologies, which may make it difficult for the company to maintain market share and margins.

Operational risk is primarily tied to the company's ability to constantly update its product range and to produce continually updated test kits in pace with market demand.

In 2011, the addition of products sold and distributed on the basis of cooperation agreements with other companies increases opportunities to strengthen market position and profitability, while it also carries an increased risk in light of the commitments with respect to resource investments and costs resulting from such agreements. The SBT products from the Australian company Conexio Genomics in particular are expected to achieve significant sales. At the same time, this involves significant competition and market risk. Establishing the products has proven to take longer than planned and there is a risk that they may not attain the anticipated success. The ability to deliver the right quality on time has both a short and long term significance for the business. For example, the inability of the partner to deliver due to production downtime could have a substantial negative effect on sales.

The transplantation test XM-ONE® is primarily used as a research product by larger centers. Work is underway to get the product established in broad clinical use. This has proven to take longer than planned and there is a risk that the product may not attain the success anticipated. This in turn could have a negative on the value of the company's intangible assets and other assets. To date, XM-ONE® is a unique product in its area and has signifi-

cant patent protection. However, there is a risk that the company's competitors may challenge these patents or otherwise introduce competing test methods.

A large part of Allenex sales are carried out in currencies other than SEK, mostly in EUR but also in USD. A lesser portion of purchases are also made in other currencies than SEK. This may signify a currency risk for the company. Allenex does not conduct currency hedging activities.

Attracting and maintaining qualified personnel for development, production, marketing, sales, logistics and administration is essential to group performance.

The value of the company is partly dependent on its ability to maintain and protect patents, other intellectual property rights and specific expertise. Patent protection for medical, medtech and biotech products can be uncertain and involve complex legal and technical issues. Patents must usually be sought and maintained in several jurisdictions, and issued patents may be challenged, invalidated and circumvented. For Allenex or its subsidiaries this may mean loss of or shortened patent protection, which in turn may mean that the company cannot prevent competitors from marketing similar products. The uncertainty associated with patents and patent litigation and other patent processes, may have a negative impact on the competitiveness of Allenex and its subsidiaries

Both clinical trials and the marketing and sales of products pose a significant risk in terms of product liability. When deemed necessary, the company obtains product liability insurance. No assurance can be given that insurance will cover future claims against Allenex or its subsidiaries.

Some of the companies are dependent on approval through clinical trials or decisions from public authorities. There are no guarantees that an associated company will achieve satisfactory results in such trials, or that the required regulatory approval will be granted.

The group's customer relations are stable and long-term, with historically low credit losses. Credit evaluations are carried out on new customers. Credit risk is currently assessed as low, but any change in a negative direction could impact the company's results and financial position.

The company has reduced its leverage risk by repaying the Allenex convertible loan (KV1) in full. Remaining is the leverage risk associated with the acquisition of Ole-rup SSP in June 2008 with a convertible loan of SEK 31 million from SSP Primers AB, which is due in June 2013.

Part of the financing was raised at variable interest rates, therefore rising interest rates could lead to lower returns for the company, which in turn could affect the company's results and financial position.

Based on the current circumstances, the group is of the opinion that it has sufficient liquidity to conduct its opera-

tions according to current plans. There is a risk that market conditions and sales will develop negatively, which may hamper ongoing financing. The group's ability to refinance maturing loans may also be adversely impacted by group performance and overall conditions in the financial markets.

The company's cash and cash equivalents are placed in liquid assets with low credit risk.

PARENT COMPANY

Revenues for the year amounted to SEK 2.6 million (3.2). Operating loss for the year was SEK 13.7 million (-27.3). The divestment of two associated companies resulted in a capital gain of SEK 1.0 million. Allenex intra-group receivables amounted to SEK 99.9 million (92.1). Cash and cash equivalents totaled SEK 5.5 million (55.3). Cash flow from operations before changes in working capital for the year was negative at SEK 17.9 million (-31.1). At year end the parent company had 4 employees (6).

SHARE AND SHAREHOLDERS

Principal owners Dec 31, 2012	No. shares	Holdings %
Mohammed Al Amoudi	43,678,850	36.3
FastPartner AB (publ)	38,886,307	32.3
Xenella Holding AB *)	11,174,755	9.3
Mannersons Fastighets AB	6,774,152	5.6
Länsförsäkringar småbolagsfond	3,327,500	2.8
Avanza Pension	1,937,259	1.6
Ingemar Lagerlöf	1,370,214	1.1
Other	13,139,411	11.0
<i>Total</i>	120,288,448	100.0

*) Xenella Holding AB is jointly owned by Mohammed Al Amoudi and FastPartner AB (publ).

Accounting principles

Allenex applies International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. This interim report was prepared in accordance with IAS 34 and the Annual Accounts Act for the group and in accordance with the Annual Accounts Act for the parent company.

The accounting principles applied for the group and the parent company are consistent with those used in the preparation of the most recent Annual Report.

Future report dates

Interim report January-March: April 25, 2013

Annual Report 2012: published latest May 3, 2013

Interim report January-June: August 2013

Interim report January-September: November 2013

The Annual General Meeting will be held in Stockholm on May 23, 2013. Shareholders wishing to have matters addressed at the meeting should submit their proposals in writing to the company at the following address: Allenex AB (publ), Attn AGM 2013, Box 122 83, 102 27 Stockholm or via email to arsstamma@allenex.se. All proposals must be received by Allenex by April 11, 2013 at the latest, or in sufficient time in order to guarantee that their proposals, if so required, may be included in the AGM notice.

Stockholm, February 21, 2013

Anders Karlsson
CEO

This year-end report has not been subject to review by the company's auditors.

The information in this interim report is such that Allenex AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This report and earlier financial reports are available at www.allenex.com

This information was released for publication on February 21, 2013 at 14.00 CET

ALLENEX[®]

Consolidated statement of comprehensive income

	2012	2011	2012	2011
Amount in SEK thousand	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC ¹⁾
Net sales	27,364	27,464	112,688	98,712
Changes in inventory of finished goods	-564	-1,076	220	-2,225
Work performed by group for its own use and capitalized	-	732	-	5,153
Other revenue	862	1,116	3,445	3,662
	27,662	28,236	116,353	105,302
Raw materials and consumables	-5,795	-4,070	-18,089	-16,599
Other expenses	-11,500	-12,030	-44,770	-49,236
Cost of employee remuneration	-9,244	-12,873	-43,299	-51,760
Depreciation/amortization	-548	-676	-2,262	-1,864
Impairment losses on intangible assets	0	-74,604	0	-74,604
Results from participations in associated companies reported in accordance with the equity method ¹⁾	-	0	-	668
<i>Operating income/loss</i>	575	-76,017	7,933	-88,093
Change in value/impairment of investments in associated companies	0	-730	0	-414,687
Results from associated companies	0	-	1,050	-
Other financial expenses and income	-904	-1,115	-6,548	-11,008
<i>Results after financial items</i>	-329	-77,862	2,435	-513,788
Taxes	1,179	6,130	-2,160	9,125
<i>Net income/loss for the period</i>	850	-71,732	275	-504,663
Other comprehensive results for the period				
Translation differences	525	-855	779	-695
<i>Comprehensive results for the period</i>	1,375	-72,587	1,054	-505,358
Results for the period pertaining to:				
Owners of the parent company	3,983	-67,420	4,452	-498,572
Non-controlling interests	-3,133	-4,312	-4,177	-6,091
Comprehensive results for the period pertaining to:				
Owners of the parent company	4,303	-68,002	4,655	-498,851
Non-controlling interests	-2,928	-4,585	-3,601	-6,507
Earnings/loss per share, basic and diluted, SEK ²⁾	0.03	-0.75	0.04	-7.23
Average number of outstanding shares, basic and diluted ²⁾	120,288,448	89,987,262	120,288,448	69,000,080
Number of shares at the period-end	120,288,448	120,288,448	120,288,448	120,288,448

¹⁾ Olerup International AB was incorporated as a subsidiary on June 1, 2011. Olerup International AB in turn owns 100% of Olerup GmbH.

²⁾ Translation of historical values was made with respect to the bonus element of the rights issue in November 2011

Consolidated statement of financial position		
	2012	2011
Amount in SEK thousand	DEC 31	DEC 31
Assets		
Goodwill	214,541	214,808
Intangible assets	64,220	65,086
Tangible assets	4,496	5,968
Participations in associated companies and other holdings	0	0
Deferred tax assets	8,711	10,389
<i>Total non-current assets</i>	<i>291,968</i>	<i>296,251</i>
Inventories	21,701	21,050
Current receivables	14,912	13,102
Cash and cash equivalents	14,327	80,530
<i>Total current assets</i>	<i>50,940</i>	<i>114,682</i>
Total assets	342,908	410,933
Equity and liabilities		
Equity	216,196	219,810
Interest-bearing non-current liabilities	18,000	90,166
Non-interest bearing non-current liabilities and provisions	13,172	15,162
Interest-bearing current liabilities	80,774	59,817
Non-interest bearing current liabilities and provisions	14,766	25,978
Total equity and liabilities	342,908	410,933

Consolidated statement of changes in equity		
	2012	2011
Amount in SEK thousand	DEC 31	DEC 31
Opening balance	219,810	575,609
Rights issue	-	154,656
Issue costs	-	-6,709
Deferred tax on issue costs	-	1,764
Dividends paid to non-controlling interests	-4,668	-3,235
Acquisition of companies with non- controlling interests	-	3,083
Comprehensive results for the period	1,054	-505,358
<i>Closing balance</i>	<i>216,196</i>	<i>219,810</i>
Of which pertaining to:		
Owners of the parent company	222,025	222,038
Non-controlling interests	5,829	-2,228

Consolidated statement of cash flows		
	2012	2011
Amount in SEK thousand	JAN-DEC	JAN-DEC
Results before financial items	7,933	-88,093
Adjustment for items not included in the cash flow	3,794	75,066
Financial items	-7,353	-11,414
Taxes paid	-3,770	-1,192
<i>Cash flow from operations before changes in working capital</i>	<i>604</i>	<i>-25,633</i>
Increase (-)/Decrease(+) in inventories	-890	485
Increase (-)/Decrease(+) in operating receivables	-3,450	3,578
Increase (-)/Decrease(+) in operating liabilities	-7,025	-305
<i>Cash flow from operating activities</i>	<i>-10,761</i>	<i>-21,875</i>
Cash flow from investing activities ¹⁾	961	-15,329
Cash flow from financing activities ^{2) 3)}	-56,403	86,535
Cash flow for the year	-66,203	49,331
Cash and cash equivalents at the start of the year	80,530	31,199
<i>Cash and cash equivalents at the year end</i>	<i>14,327</i>	<i>80,530</i>

- 1) Divestment of associates included at an amount of SEK 1,050 thousand (0).
- 2) Dividends to a non-controlling interest are incl. at SEK 4,668 thousand (3,235).
- 3) Convertible loan "KV1" repaid in full at an amount of SEK 40,776 thousand as well as the amortization of a bank loan at SEK 12,000 thousand.

Parent company income statement

	2012		2011	
	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Amount in SEK thousand				
Other revenues	650	1,340	2,552	3,219
Other external expenses	-2,065	-3,318	-8,477	-15,045
Personnel expenses	-1,353	-3,773	-7,625	-15,365
Depreciation/amortization	-43	-44	-174	-163
<i>Operating results</i>	<i>-2,811</i>	<i>-5,795</i>	<i>-13,724</i>	<i>-27,354</i>
Impairment of part. In associated companies	0	-730	0	-254,219
Impairment of shares in subsidiaries	-2,000	-116,732	-2,000	-116,732
Results from divestment of associated companies	0	-	1,050	-
Other financial expenses and revenues	-187	-759	237	-3,576
<i>Results after financial items</i>	<i>-4,998</i>	<i>-124,016</i>	<i>-14,437</i>	<i>-401,881</i>
<i>Allocations</i>				
Group contributions received	31,648	31,102	31,648	31,102
Group contributions paid	-16,618	-	-16,618	-
<i>Earnings before tax</i>	<i>10,032</i>	<i>-92,914</i>	<i>593</i>	<i>-370,779</i>
Tax	-297	-10,525	-297	-3,702
<i>Net income/loss for the year</i>	<i>9,735</i>	<i>-103,439</i>	<i>296</i>	<i>-374,481</i>

Statement of comprehensive income for the parent company

Results for the period	9,735	-103,439	296	-374,481
<i>Other comprehensive results for the period</i>	-	-	-	-
<i>Comprehensive results for the period</i>	<i>9,735</i>	<i>-103,439</i>	<i>296</i>	<i>-374,481</i>

Parent company balance sheet

	2012		2011	
	DEC 31		DEC 31	
Amount in SEK thousand				
Assets				
Intangible and tangible assets	322	468		
Shares in subsidiaries	57,378	57,378		
Participations in associated companies	0	0		
Non-current intra-group receivables	99,872	92,122		
Deferred tax assets	1,626	1,923		
<i>Total non-current assets</i>	<i>159,198</i>	<i>151,891</i>		
Current receivables	38,128	38,794		
Cash and bank	5,480	55,320		
<i>Total current assets</i>	<i>43,608</i>	<i>94,114</i>		
Total assets	202,806	246,005		
Equity and liabilities				
Equity	163,621	163,325		
Non-current liabilities	0	30,058		
Current liabilities	39,185	52,622		
Total equity and liabilities	202,806	246,005		
Changes in equity, parent company				
Opening balance	163,325	388,096		
Rights issue	-	154,655		
Issue costs	-	-6,709		
Deferred tax on emissions tax	-	1,764		
Net income/loss for the year	296	-374,481		
Closing balance	163,621	163,325		

Parent company statement of cash flows

	2012	2011
Amount in SEK thousand	JAN-DEC	JAN-DEC
Results before financial items	-13,724	-27,354
Adjustments for items not included in the cash flow	174	187
Financial items	-4,320	-6,289
Taxes paid	0	0
<i>Cash flow from operating activities before changes in working capital</i>	<i>-17,870</i>	<i>-33,456</i>
Increase (-)/Decrease(+) in operating receivables	441	1,244
Increase (-)/Decrease(+) in operating liabilities	-3,909	-2,324
<i>Cash flow from operating activities</i>	<i>-21,338</i>	<i>-34,536</i>
Cash flow from investing activities ^{1) 2)}	12,274	-29,451
Cash flow from financing activities ³⁾	-40,776	101,870
Cash flow for the year	-49,840	37,883
Cash and cash equivalents at the start of the year	55,320	17,437
<i>Cash and cash equivalents at the end of the year</i>	<i>5,480</i>	<i>55,320</i>

¹⁾ Received subsidiary dividend totaling SEK 2,400 thousand (2,400).

²⁾ Divestment of associated company at a total compensation of SEK 1,050 thousand (0)

³⁾ Convertible loan "KV1" repaid by SEK 40,776.

Key figures

	2012	2011
	JAN-DEC	JAN-DEC
Net sales, SEK thousand	112,688	98,712
Operating income/loss, SEK thousand	7,933	-88,093
Net income/loss after tax, SEK thousand	275	-504,663
Earnings/loss per share, basic and diluted, SEK ¹⁾	0.04	-7.23
Equity per share, SEK	1.80	1.83
Equity/assets ratio, %	63	53
Return on equity, %	2	-225
Average number of employees	54	60
Fair value of portfolio of associated companies, SEK thousand	0	0
Book value of portfolio of associated companies, SEK thousand	0	0
Number of shares outstanding at the year end	120,288,448	120,288,448
Average number of shares outstanding ¹⁾	120,288,448	69,000,080
Share price at the year end, SEK	0.85	1.49
Market cap, SEK thousand	102,245	179,230

¹⁾ Translation of historical values was made with respect to the bonus element of the rights issue in November 2011.

Definitions:

Earnings per share

Equity per share

Equity/assets ratio

Earnings after tax divided by the average number of outstanding shares.

Equity divided by the number of outstanding shares at the period end.

Equity at the period end in relation to total assets.

Companies in the Allenex group

MANUFACTURING AND R&D COMPANIES



Olerup SSP AB is world leading in the development of kits for genomic HLA typing, based on SSP technology. The product is used prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to bone marrow transplantation (hematopoietic stem cell transplantation) and is also used in conjunction with organ transplants (kidney, lung, heart, etc.). In 2011, Olerup SSP entered into a five-year exclusive global agreement (excl. Australia, New Zealand and Taiwan) with Conexio Genomics, Perth, Australia. Allenex's ownership stake in Olerup SSP AB is 91 percent. For more information visit www.olerup-ssp.com



AbSorber develops products that facilitate successful transplantation. AbSorber's transplantation test XM-ONE®, identifies antibodies that play a key role in causing rejection subsequent to transplantation. The company's research portfolio also includes a patented ABO column for transplantations between people of different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies. Allenex's ownership stake of AbSorber is 98 percent. For more information visit www.absorber.se

SALES AND DISTRIBUTION COMPANIES



Olerup GmbH, based in Vienna, is responsible for sales, distribution and logistics in Europe and the rest of the world excluding North, Central and South America as well as the Nordic region. Sales encompass Olerup SSP's HLA typing products and AbSorber's XM-ONE® transplantation test. Furthermore, from mid-year 2011, the company also sells and distributes products from the Australian company Conexio Genomics. Sales are conducted by a proprietary sales team in Germany, Austria and Slovenia, as well as the Nordic region. From May 1, 2012, Olerup GmbH also started selling directly to end-customers in the Netherlands and Belgium. Sales in other markets are handled by sub-distributors. The company is owned by Olerup International, in which Allenex has an ownership stake of 75 percent. For more information visit www.olerup.com



Olerup Inc., domiciled in West Chester, PA, USA, is responsible for the sales, distribution and logistics of Olerup SSP and AbSorber products in the North American market. Furthermore, since mid-2011, the company sells and distributes products from the Australian company Conexio Genomics. The company has its own sales organization in the US, while sales in Canada and Central and South America are handled by sub-distributors. AbSorber owns 50 percent of the company. For more information visit www.olerup.com